These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16806963)

  • 1. Cetuximab in advanced non-small cell lung cancer.
    Rossi A; Maione P; Gridelli C
    Crit Rev Oncol Hematol; 2006 Aug; 59(2):139-49. PubMed ID: 16806963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancer.
    Rossi A; Bria E; Maione P; Palazzolo G; Falanga M; Gridelli C
    Rev Recent Clin Trials; 2008 Sep; 3(3):217-27. PubMed ID: 18782080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab in advanced non-small cell lung cancer.
    Govindan R
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4241s-4244s. PubMed ID: 15217966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies against EGFR in non-small cell lung cancer.
    Pirker R; Filipits M
    Crit Rev Oncol Hematol; 2011 Oct; 80(1):1-9. PubMed ID: 21109448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab in non-small-cell lung cancer.
    Carillio G; Montanino A; Costanzo R; Sandomenico C; Piccirillo MC; Di Maio M; Daniele G; Giordano P; Bryce J; Normanno N; Rocco G; Perrone F; Morabito A
    Expert Rev Anticancer Ther; 2012 Feb; 12(2):163-75. PubMed ID: 22316364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a role for cetuximab in non small cell lung cancer?
    Morgensztern D; Govindan R
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4602-5. PubMed ID: 17671149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor.
    Steiner P; Joynes C; Bassi R; Wang S; Tonra JR; Hadari YR; Hicklin DJ
    Clin Cancer Res; 2007 Mar; 13(5):1540-51. PubMed ID: 17332300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolving role of cetuximab in non-small cell lung cancer.
    Lilenbaum RC
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4432s-4435s. PubMed ID: 16857823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments.
    Gridelli C; Maione P; Rossi A; De Marinis F
    Oncologist; 2007 Oct; 12(10):1183-93. PubMed ID: 17962612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical relevance of monoclonal antibodies in non small cell lung cancer.
    Filipits M
    J BUON; 2009 Sep; 14 Suppl 1():S147-52. PubMed ID: 19785057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetuximab: potential role as first-line treatment for advanced non-small cell lung cancer.
    Pirker R
    Clin Adv Hematol Oncol; 2008 Oct; 6(10):735-6. PubMed ID: 18997663
    [No Abstract]   [Full Text] [Related]  

  • 12. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer.
    Agelaki S; Georgoulias V
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):855-74. PubMed ID: 16262567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR-directed therapies to treat non-small-cell lung cancer.
    Ho C; Laskin J
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1133-45. PubMed ID: 19572809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer.
    Gridelli C; Maione P; Ferrara ML; Rossi A
    Oncologist; 2009 Jun; 14(6):601-11. PubMed ID: 19482958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of EGFR inhibition in the treatment of non-small cell lung cancer.
    Ray M; Salgia R; Vokes EE
    Oncologist; 2009 Nov; 14(11):1116-30. PubMed ID: 19892771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unanswered questions: monoclonal antibodies in the treatment of advanced non-small-cell lung cancer.
    Gridelli C; Rossi A
    Oncology (Williston Park); 2010 Nov; 24(13):1216-23. PubMed ID: 21192561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controversies around the use of monoclonal antibodies in the treatment of advanced non-small cell lung cancer.
    Dediu M; Ion O; Ion R; Gal C; Median D; Gongu M
    J BUON; 2009 Sep; 14 Suppl 1():S159-64. PubMed ID: 19785059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor.
    Kelly K; Huang C
    J Thorac Oncol; 2008 Jun; 3(6):664-73. PubMed ID: 18520811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer.
    Thienelt CD; Bunn PA; Hanna N; Rosenberg A; Needle MN; Long ME; Gustafson DL; Kelly K
    J Clin Oncol; 2005 Dec; 23(34):8786-93. PubMed ID: 16246975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Stage IV NSCLC. Biological treatments of lung cancer in 2008... and in the near future].
    Bergot E; Levallet G; Zalcman G
    Rev Mal Respir; 2008 Oct; 25(8 Pt 2):3S119-26. PubMed ID: 18971836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.